Nature Communications - A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Lopez-Serra P, M >>


Cell Reports - Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk.Heyn H, Sayols S, Moutinho C >>


Cancer Discovery - MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal wit >>


Genome Research - DNA methylation contributes to natural human variation. Heyn H, Moran S, Hernando-Herraez I, Sayols  >>


Genes & Development - Serrano, L., Martinez-Redondo, P., Marazuela-Duque, A., Vazquez, B.N., Kane-Goldsmith, N., Dooley, S >>


Proc Natl Acad Sci USA - Heyn H, Li N, Ferreira HJ, Moran S, Pisano DG, Gomez A, Diez J, Sanchez-Mut JV, Setien F, Carmona FJ >>


Nature Structural & Molecular Biology - Guil S, Soler M, Portela A, Carrere J, Fonalleras E, Gomez A, Villanueva A, Esteller M. Intronic RNA >>



PEBC in "Molecular Cell" and "Nature"

Dr Manel Esteller

In the early summer of 2014, the PEBC research has been recognized in the prestigious journals "Molecular Cell" and "Nature". For more information: -Liz J, Portela A, Soler M, Gómez A, Ling H, Michlewski G, Calin GA, Guil S, Esteller M. RNA-Directed Regulation of pri-miRNA Processing by a Long Noncoding RNA Transcribed from an Ultraconserved Region. Molecular Cell, doi: 10.1016/j.molcel.2014.05.005, 2014. -Ongen H, Andersen CL, Bramsen JB, Oster B, Rasmussen MH, Ferreira PG, Sandoval J, Vidal E, Whiffin N, Planchon A, Padioleau I, Bielser D, Romano L, Tomlinson I, Houlston RS, Esteller M, Orntoft TF, Dermitzakis ET. Putative cis-regulatory drivers in colorectal cancer. Nature, doi:10.1038/nature13602, 2014.


Back-to-back Discoveries of PEBC in Rett Syndrome

Dr Manel Esteller

We have at PEBC a long standing interest in rare disorders, particularly genetic syndromes affecting epigenetic genes. This is the case of Rett syndrome, the second most common cause of intellectual disability in women that it is associated with MeCP2 mutations. Two PEBC recent articles show how an excess of MeCP2 impairs neuronal function and how Parkinson’s drugs might be usel in reducing the phenotype of the mice that mimics the Rett syndrome. References: Petazzi P, Akizu N, Garcia A, Estarás C, Martinez de Paz A, Rodríguez-Paredes M, Martínez-Balbás M, Huertas D, Esteller M. An Increase in MeCP2 Dosage Impairs Neural Tube Formation. Neurobiology of Disease, 67C, 49-56, 2014. Szczesna K, de la Caridad O, Petazzi P, Soler M, Roa L, Saez MA, Fourcade S, Pujol A, Artuch-Iriberri R, Molero-Luis M, Vidal A, Huertas D, Esteller M. Improvement of the Rett Syndrome Phenotype in a Mecp2 Mouse Model Upon Treatment with Levodopa and a Dopa Decarboxylase Inhibitor. Neuropsychopharmacology, doi: 10.1038/npp.2014.136, 2014.


PEBC in “Nature Communications” and “Cell Reports”

Dr Manel Esteller

The research developed at the PEBC has been recognized in the prestigious journals “Nature Communications” and “Cell Reports”. For further information: -A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Lopez-Serra P, Marcilla M, Villanueva A, Ramos-Fernandez A, Palau A, Leal L, Wahi JE, Setien-Baranda F, Szczesna K, Moutinho C, Martinez-Cardus A, Heyn H, Sandoval J, Puertas S, Vidal A, Sanjuan X, Martinez-Balibrea E, Viñals F, Perales JC, Bramsem JB, Ørntoft TF, Andersen CL, Tabernero J, McDermott U, Boxer MB, Heiden MG, Albar JP, Esteller M. Nat Commun. 2014 Apr 3;5:3608. doi: 10.1038/ncomms4608. -Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk. Heyn H, Sayols S, Moutinho C, Vidal E, Sanchez-Mut JV, Stefansson OA, Nadal E, Moran S, Eyfjord JE, Gonzalez-Suarez E, Pujana MA, Esteller M. Cell Rep. 2014 Apr 2. pii: S2211-1247(14)00194-6. doi: 10.1016/j.celrep.2014.03.016.


Manel Esteller, “Vanguardia de la Ciencia” Award

Dr Manel Esteller

Dr. Manel Esteller, Director of the Cancer Epigenetics and Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), ICREA Researcher and Professor of Genetics at the University of Barcelona has been awarded with the “Vanguardia de la Ciencia” Award. The selected publication was posted in Genome Research in 2013 and shows the existence of epigenetic differences between different populations that could explain the different susceptibility to some diseases. The finalists have been selected by a Scientific Committee on the basis of two criteria: the scientific excellence and that the director and /or the first author of the research works in Spain. Dr. Esteller has been invited to present his results to the public during the ceremony in which he will receive the prize, together with the three most voted finalists. The act is scheduled for April 24th at “La Pedrera” building, headquarters of the “Fundació Catalunya - La Pedrera”. Organized by “Grupo Godo” together with “Fundació Catalunya - La Pedrera”, the objective of this yearly prize is to disseminate the Spanish research excellence. This year, in its fourth edition, 33.620 readers participated in the election by voting at the web www.lavanguardia.com, what means a new participation record. http://www.lavanguardia.com/vanguardia-de-la-ciencia/20140309/54402190712/manel-esteller-premio-vanguardia-de-la-ciencia.html


The PEBC and Pasqual Maragall Foundation together against Alzheimer

Dr Manel Esteller

Alzheimer's disease can reach epidemic status in the coming decades, helped by the increasing average age of the society. There are two key problems in this disease: there isn't any effective treatment and only a few genetic alterations (mutations) associated with its appearance have been described, reducing the target for future therapies. To reinforce research in this disease, the Cancer Epigenetics and Biology Program and the Pasqual Maragall Foundation, represented by their Directors (Dr. Manel Esteller and Dr. Jordi Camí), have established a strategic alliance to investigate Alzheimer’s genetic and epigenetic basis to improve the diagnosis and treatments of this disease.



© 2008® | PEBC | Todos los derechos reservados |  WEBMAIL  |  INTRANET  |  FTP